Supplementary file 1_Therapeutic effects of Balanites aegyptiaca DEL extract on diabetes mellitus: a systematic review.pdf by Olubukola Adebisi Odeniran (22162777)

“…Significant decrease in blood glucose level was recorded in Alloxan- and streptozotocin-induced rat/mice diabetes. …”

Table 3_How does ego depletion reduce sports performance in athletes? A systematic meta-analysis.docx by Xu Yan (110026)

“…After sensitivity analyses using the Leave-One-Out method, two articles and one experiment were excluded with significant effect sizes. The final total effect size of ego depletion on athletes’ sports performance SMD = −0.38 [95% CI: −0.56 to −0.21], P = 0.001, demonstrating that ego depletion can produce a decrease in athletes’ sports performance. …”

Supplementary file 2_Therapeutic effects of Balanites aegyptiaca DEL extract on diabetes mellitus: a systematic review.pdf by Olubukola Adebisi Odeniran (22162777)

“…Significant decrease in blood glucose level was recorded in Alloxan- and streptozotocin-induced rat/mice diabetes. …”

Table 2_How does ego depletion reduce sports performance in athletes? A systematic meta-analysis.docx by Xu Yan (110026)

“…After sensitivity analyses using the Leave-One-Out method, two articles and one experiment were excluded with significant effect sizes. The final total effect size of ego depletion on athletes’ sports performance SMD = −0.38 [95% CI: −0.56 to −0.21], P = 0.001, demonstrating that ego depletion can produce a decrease in athletes’ sports performance. …”

Table 1_How does ego depletion reduce sports performance in athletes? A systematic meta-analysis.xlsx by Xu Yan (110026)

“…After sensitivity analyses using the Leave-One-Out method, two articles and one experiment were excluded with significant effect sizes. The final total effect size of ego depletion on athletes’ sports performance SMD = −0.38 [95% CI: −0.56 to −0.21], P = 0.001, demonstrating that ego depletion can produce a decrease in athletes’ sports performance. …”

CONSORT diagram of the study. by Plaiwan Suttanon (4741197)

“…The control group showed a significant increase in COM angle sway excursion (lateral direction) (p = 0.011, d = 0.27, 95% CI [-0.19, 0.74]) and a decrease in TMT-A time (p = 0.031, d = 0.38, 95% CI [-0.09, 0.85]). …”

[A] Histopathological images of pancreas, liver, kidney, and heart tissues from the studied rat groups, stained with H&E. by Mohamed Lotfy (18599184)

“…Pancreas: Untreated diabetic rats show a reduction in the size of pancreatic islets of Langerhans (IL), correlated with a decrease in insulin-secreting beta cells. …”

Table 1_Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma.docx by Zhou Liu (1506679)

“…<p>This case report describes a geriatric male patient with myasthenia gravis (MG) secondary to giant thymoma, presenting with progressive muscle weakness and ptosis. …”

Table 1_Spatial stratified heterogeneity of mumps incidence in China: a Geodetector-based analysis of driving factors.xlsx by Ke Hu (84619)

“…</p>Results<p>The findings revealed a distinct west-to-east decreasing trend of mumps incidence in China, demonstrating significant spatial autocorrelation primarily manifested as high-high clustering in western areas and low-low clustering in eastern regions. …”

Data Sheet 1_Fatty infiltration and cross-sectional area as indicators of muscle mass in osteoporosis: a meta-regression study.pdf by Genwen Sun (22678739)

“…Three-level meta-regression models were implemented to examine the influence of study-level moderators, including age, sex, measurement level and comparison category.</p>Results<p>A significant decrease in CSA was observed only in osteoporotic patients compared with controls, and multiple muscle groups were evaluated. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Supplementary Material for: Early initiation of icodextrin reduces peritoneal dialysis-associated peritonitis risk: a retrospective cohort study by Mitsuno R. (20394647)

“…The early use of ICO remained significantly associated with decreased incidence of both peritonitis and TI (hazards ratio [HR], 0.19; 95% confidence interval [CI], 0.06–0.69 and HR, 0.10; 95% CI, 0.01–0.78, respectively) using Cox regression analysis adjusted for potential confounders. …”

Data Sheet 1_Cardiovascular outcomes in adult patients with atrial septal defect: a nationwide population-based study.docx by Jue Seong Lee (14992676)

“…Over a 5-year follow-up period, the adjusted hazard ratios for MACE were significantly lower in the surgery (0.72; 95% CI: 0.66–0.79) and device closure groups (0.85; 95% CI: 0.78–0.92) than in the observation group. …”